Rudolf Jaenisch

Rudolf Jaenisch
Rudolf Jaenisch, 2003
Born	(1942-04-22) 22 April 1942 (age 74) Wölfelsgrund, Germany
Residence	Germany, USA
Citizenship	German
Fields	Biochemistry Genetics Medicine
Institutions	Max Planck Institute for Biochemistry Princeton University Fox Chase Cancer Center Salk Institute Heinrich Pette Institute University of Hamburg Whitehead Institute for Biomedical Research Massachusetts Institute of Technology
Alma mater	University of Munich (M.D., 1967)
Academic advisors	Arnold Levine
Known for	Epigenetic mechanisms of gene regulation Therapeutic cloning Embryonic stem cell research
Notable awards	Boehringer Mannheim Molecular Bioanalytics Prize (1996) Gruber Prize in Genetics (2001) Robert Koch Prize (2002) Max Delbrück Medal (2006) Massry Prize from the Keck School of Medicine (2008) Wolf Prize in Medicine (2011) National Medal of Science (2011)
Website wi.mit.edu/people/faculty/jaenisch

Rudolf Jaenisch (born 22 April 1942) is a Professor of Biology at MIT and a founding member of the Whitehead Institute for Biomedical Research. He is a pioneer of transgenic science, in which an animal’s genetic makeup is altered. Jaenisch has focused on creating genetically modified mice to study cancer and neurological diseases.

Jaenisch’s first breakthrough occurred in 1974 when he and Beatrice Mintz showed that foreign DNA could be integrated into the DNA of early mouse embryos. They injected retrovirus DNA into early mouse embryos and showed that leukemia DNA sequences had integrated into the mouse genome and also to its offspring. These mice were the first transgenic mammals in history.

His current research focuses on the epigenetic regulation of gene expression, which has led to major advances in creating embryonic stem cells and “induced pluripotent stem" (IPS) cells, as well as their therapeutic applications. In 2007, Jaenisch’s laboratory was one of the first three laboratories world-wide to report reprogramming cells taken from a mouse's tail into IPS cells. Jaenisch has since shown therapeutic benefits of IPS cell-based treatment for sickle-cell anemia and Parkinson's disease in mice. Additional research focuses on the epigenetic mechanisms involved in cancer and brain development.

Jaenisch’s therapeutic cloning research deals exclusively with mice, but he is an advocate for using the same techniques with human cells in order to advance embryonic stem cell research. However, in 2001 Jaenisch made a public case against human reproductive cloning, testifying to a U.S. House of Representatives subcommittee and an editorial in Science magazine.